-
Biology of Bladder Cancer (R01 Clinical Trial Optional)
(PAR-19-183)
National Cancer Institute
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
The first standard application due date for this FOA is June 5, 2019.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Biology of Bladder Cancer (R21 Clinical Trial Optional)
(PAR-19-184)
National Cancer Institute
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
The first standard application due date for this FOA is June 16, 2019.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Centers for Medical Countermeasures Against Radiation Consortium (U19 Clinical Trial Not Allowed)
(RFA-AI-19-012)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): May 31, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Functional RNA Modifications Environment and Disease (FRAMED) (R01 Clinical Trial Not Allowed)
(RFA-ES-19-001)
National Institute of Environmental Health Sciences
Application Receipt Date(s): May 16, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Functional RNA Modifications Environment and Disease (FRAMED) (R21 Clinical Trial Not Allowed)
(RFA-ES-19-002)
National Institute of Environmental Health Sciences
Application Receipt Date(s): May 16, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Innovative Approaches for Improving Environmental Health Literacy (R43/R44 Clinical Trial Not Allowed)
(RFA-ES-19-005)
National Institute of Environmental Health Sciences
Application Receipt Date(s): April 9, 2019, by 5:00 PM local time of applicant organization.
-
Innovative Approaches for Improving Environmental Health Literacy (R41/R42 Clinical Trial Not Allowed)
(RFA-ES-19-006)
National Institute of Environmental Health Sciences
Application Receipt Date(s): April 9, 2019 by 5:00 PM local time of applicant organization.
-
Bioequivalence of Topical Products: Bioequivalence Considerations for Ungual, Scalp, Vaginal, Anal or Rectal Dosage Forms (U01 Clinical Trial Not Allowed)
(RFA-FD-19-008)
Food and Drug Administration
Application Receipt Date(s): April 11, 2019, by 11:59 PM Eastern Time.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
-
Bioequivalence of Topical Products: Elucidating the Sensorial and Functional Characteristics of Compositionally Different Topical Formulations (U01 Clinical Trial Required)
(RFA-FD-19-009)
Food and Drug Administration
Application Receipt Date(s): April 11, 2019, by 11:59 PM Eastern Time.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
-
Bioequivalence of Topical Products: Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Not Allowed)
(RFA-FD-19-010)
Food and Drug Administration
Application Receipt Date(s): April 11, 2019, by 11:59 PM Eastern Time.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
-
Patient Reported Outcomes Tool Development for Use in Non-Cystic Fibrosis Bronchiectasis Clinical Trials (U01- Clinical Trial Required)
(RFA-FD-19-014)
Food and Drug Administration
Application Receipt Date(s): April 4, 2019, by 11:59 PM Eastern Time.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
-
Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings and Developmental Transitions (R34 Clinical Trial Required)
(RFA-MH-20-100)
National Institute of Mental Health
Application Receipt Date(s): May 1, 2019 and November 15, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
No Late Applications will be accepted for this Funding Opportunity Announcement.
-
Secondary Data Analysis to Examine Long-Term and/or Potential Cross-Over Effects of Prevention Interventions: What are the Benefits for Preventing Mental Health Disorders? (R01 Clinical Trial Not Allowed)
(RFA-MH-20-110)
National Institute of Mental Health
National Center for Complementary and Integrative Health
Office of Research on Women's Health
Application Receipt Date(s): May 2, 2019; January 2, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
No late applications will be accepted for this Funding Opportunity Announcement.
-
Biological Measures for Prognosing and Monitoring of Persistent Concussive Symptoms in Early and Middle Adolescents: Center Without Walls (PCS-EMA CWOW) (U54 Clinical Trial Not Allowed)
(RFA-NS-19-022)
National Institute of Neurological Disorders and Stroke
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): April 10, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
No late applications will be accepted for this Funding Opportunity Announcement.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed)
(RFA-OD-19-015)
National Institutes of Health
National Institute on Aging
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Cancer Institute
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Eye Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute of Neurological Disorders and Stroke
National Center for Complementary and Integrative Health
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Application Receipt Date(s): March 14, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity are due on this date. No late applications will be accepted for this Funding Opportunity Announcement.
-
Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)
(RFA-OD-19-016)
National Institutes of Health
National Institute on Aging
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Cancer Institute
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Eye Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute of Neurological Disorders and Stroke
National Center for Complementary and Integrative Health
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Application Receipt Date(s): March 14 2019 , by 5:00 PM local time of applicant organization.
No late applications will be accepted for this Funding Opportunity Announcement.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trials Required)
(RFA-OD-19-018)
National Institutes of Health
National Institute on Aging
National Cancer Institute
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Eye Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute of Neurological Disorders and Stroke
National Center for Complementary and Integrative Health
National Institute on Minority Health and Health Disparities
Application Receipt Date(s): March 14, 2019.
No late applications will be accepted for this Funding Opportunity Announcement.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.